Logotipo del SMU

RMU

Uruguayan Medical Journal

ISSN: 1688-0390


Vol.20 - Nº 3 - Dic. 2004

Previous Art | Index | Next Art

Localized prostate cancer: ten year-experience of tridimensional conformal radiotherapy

LEBORGNE JH; ZUBIZARRETA E; ORTEGA B; LEBORGNE DEUS J; LEBORGNE F; AGUIAR S; CUROCHQUIN R; MEZZERA J; MULLIN M; BERAZA J
Rev Med Urug 2004; 20: 193-201
Full text (spanish) |  Full text (spanish) (New windows, pdf) | Abstract

Abstract

A sample of 560 patients with localized prostate cancer were analyzed from 1993 to 2001. All patients were treated with tridimensional conformal radiotherapy.

Global survival after 9 years was 71%, while specific cause survival was 88%. Mortality due to prostate cancer was 4,8% compared to 8,3% observed in other causes mortality.

Survival without biochemical fallen again according to risk-group was 83%, 68% and 41% after 9 years, respectively for groups at low, medium and high risk in 504 patients (p<0,05). Dosage >72 Gy improved biochemical control at 7 years in the whole population but was significant only in the group at high risk (p<0,006). Cox model showed that the group at risk, total dosage at continual variable and initial PSA as categorical variable were significant.

When Cox model was employed in 188 patients at high risk, inductive or concomitant use of hormonetherapy and age became significant. Grade 3 and 4 severe complications after 10 years accounted for 1,2% and 1,4% (actuarial rates) respectively at urinary and digestive levels.

Tridimensional conformal radiotherapy at high dosage is an effective and of low morbidity treatment for localized prostate cancer.